Risk prediction of breast cancer treatment-related cardiotoxicity to guide clinical decision making

乳腺癌治疗相关心脏毒性的风险预测以指导临床决策

基本信息

  • 批准号:
    10689025
  • 负责人:
  • 金额:
    $ 36.88万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-07-01 至 2025-06-30
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY Nearly 20% of the 3 million breast cancer survivors in the U.S. have cardiovascular disease (CVD). The National Cancer Institute, NHLBI, and professional oncology and cardiology societies have all endorsed the importance of reducing CVD burden in breast cancer survivors through earlier recognition and intervention. Although women diagnosed with stages I to III breast cancer have an excellent prognosis with 5-year relative survival >90%, specific adjuvant therapies have been reported to lead to cardiovascular (CV) events that impair health-related quality of life and/or lead to premature CVD death. CV events including acute myocardial infarction, stroke, and venous thromboembolism have been reported to be associated with adjuvant chemotherapy, biological agents, radiation therapy, and/or hormonal therapies. These treatment-related CV events pose a significant public health problem because they will affect the increasing number of breast cancer survivors’ health-related quality of life over a long-life expectancy. Currently, no standard risk model exists to predict the risk of CV events associated with multiple adjuvant breast cancer therapies in the presence of established CV risk factors (such as hypertension, hyperlipidemia, smoking) to inform practice guidelines and promote shared clinical decision-making. Such models can inform women before treatment about the potential risks of CVD from alternative treatment strategies while maintaining the best chances for cancer cure. These models can also help to identify women at highest risk of CVD after therapy who would potentially benefit from earlier and more intensive CV monitoring via routine imaging and/or use of preventive medications to mitigate risk of CV events. To address this gap, our study will create risk prediction models by analyzing a large, demographically heterogeneous cohort of adult women (N=40,500) with newly diagnosed stages I to III invasive breast cancer in real-world health care settings. We will study women diagnosed from 2008-2020 and followed up to 15 years using the comprehensive electronic records of one of the largest health plans in the U.S., Kaiser Permanente. In Aim 1, we will assess incident CV events (acute myocardial infarction, stroke, heart failure) following adjuvant breast cancer therapies, adjusting for tumor characteristics and CVD risk factors such as age, race/ethnicity, pre-existing CVD, CVD medications (statins, anti-hypertensives, anti- diabetics), hypertension, diabetes, BMI, and smoking. We will then estimate whether the risk of CV events is greater in the breast cancer cohort versus an age, race- matched cancer-free cohort. In Aim 2, we will create and validate risk prediction models for early (<1 year) and late (up to 15 years) CV events. Our project will be the first to estimate the association of multiple established CVD risk factors with the risk of breast cancer adjuvant treatment-related CV events in a real-world, ethnically and socioeconomically diverse community-based cohort. Our risk prediction models will provide new information to guide evidence-based clinical decision-making concerning adjuvant therapy use for breast cancer and concurrent and post-treatment cardio-oncology care.
项目总结

项目成果

期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Influence of Comorbidity Burden, Socioeconomic Status, and Race and Ethnicity on Survival Disparities in Patients With Cancer.
  • DOI:
    10.1177/10732748231204474
  • 发表时间:
    2023-01
  • 期刊:
  • 影响因子:
    2.6
  • 作者:
    Cooper, Robert M.;Chao, Chun;Mukherjee, Amrita;Zhuang, Zimin;Haque, Reina
  • 通讯作者:
    Haque, Reina
The Influence of Medical Comorbidities on Survival Disparities in a Multiethnic Group of Patients with De Novo Metastatic Breast Cancer.
合并症对多种族新发转移性乳腺癌患者生存差异的影响。
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Reina Haque其他文献

Reina Haque的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Reina Haque', 18)}}的其他基金

Longitudinal assessment of benefits and harms of cannabis use among community-based cancer patients during initial cancer treatment
对社区癌症患者在初始癌症治疗期间使用大麻的益处和危害的纵向评估
  • 批准号:
    10790738
  • 财政年份:
    2023
  • 资助金额:
    $ 36.88万
  • 项目类别:
Risk prediction of breast cancer treatment-related cardiotoxicity to guide clinical decision making
乳腺癌治疗相关心脏毒性的风险预测以指导临床决策
  • 批准号:
    10452489
  • 财政年份:
    2020
  • 资助金额:
    $ 36.88万
  • 项目类别:
Risk prediction of breast cancer treatment-related cardiotoxicity to guide clinical decision making
乳腺癌治疗相关心脏毒性的风险预测以指导临床决策
  • 批准号:
    10062695
  • 财政年份:
    2020
  • 资助金额:
    $ 36.88万
  • 项目类别:
Risk prediction of breast cancer treatment-related cardiotoxicity to guide clinical decision making
乳腺癌治疗相关心脏毒性的风险预测以指导临床决策
  • 批准号:
    10191034
  • 财政年份:
    2020
  • 资助金额:
    $ 36.88万
  • 项目类别:
ABC: Antidepressants and Breast Cancer Pharmacoepidemiology
ABC:抗抑郁药和乳腺癌药物流行病学
  • 批准号:
    8059706
  • 财政年份:
    2010
  • 资助金额:
    $ 36.88万
  • 项目类别:
ABC: Antidepressants and Breast Cancer Pharmacoepidemiology
ABC:抗抑郁药和乳腺癌药物流行病学
  • 批准号:
    7897224
  • 财政年份:
    2010
  • 资助金额:
    $ 36.88万
  • 项目类别:
ABC: Antidepressants and Breast Cancer Pharmacoepidemiology
ABC:抗抑郁药和乳腺癌药物流行病学
  • 批准号:
    8250850
  • 财政年份:
    2010
  • 资助金额:
    $ 36.88万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 36.88万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 36.88万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 36.88万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 36.88万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 36.88万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 36.88万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 36.88万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 36.88万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 36.88万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 36.88万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了